Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
← catalyst calendarSponsored by Dogwood Therapeutics Inc. (industry) · DWTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
240estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-21 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chemotherapy Induced Neuropathic Pain
- Chemotherapy Induced Pain Neuropathy
- Chemotherapy Induced Pain
Interventions
- Drug: Halneuron
- Drug: Placebo
- Drug: Halneuron (Open Label Extension)
Primary outcomes
what the primary-completion date above is the date OFNRS Pain
measured From enrollment to end of study at 4 weeks
Safety Assessments
measured From enrollment to end of study at 4 weeks
Permalink · DWTX's whole pipeline · Catalyst calendar · Every registered study · What changed